The most conventional model for commercialising intellectual property in the life sciences sector is licensing or cross-licensing. We have experience with critical commercial issues such as:

•    appropriate licensed fields, performance obligations,
     bases for calculating royalties, industry-typical and
     product specific royalty rates;

•    milestone payments – both for development, product
     launch and post-launch;

•    provisions addressing compounding royalties
     (“anti-stacking”); and

•    steps to mitigate against the insolvency of the
     counter-party - a critical issue in the current environment.

See also:
Commercial Agreements
Data protection
Pharmaceuticals
Medical Devices
Due Diligence
Regulatory